|
|
Volumn 153, Issue 3, 2017, Pages 858-859
|
|
Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Clinical Decision Support Tool
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
BIOCHEMICAL MARKER;
CERTOLIZUMAB PEGOL;
INFLIXIMAB;
MERCAPTOPURINE;
TUMOR NECROSIS FACTOR INHIBITOR;
ANTIINFLAMMATORY AGENT;
GASTROINTESTINAL AGENT;
ARTICLE;
DECISION SUPPORT SYSTEM;
DRUG MONITORING;
ENZYME ACTIVITY;
GENOTYPE;
HUMAN;
INFLAMMATORY BOWEL DISEASE;
MONOTHERAPY;
PRIORITY JOURNAL;
REMISSION;
TREATMENT RESPONSE;
ALGORITHM;
CLINICAL PATHWAY;
GASTROENTEROLOGY;
PREDICTIVE VALUE;
STANDARDS;
TREATMENT OUTCOME;
ALGORITHMS;
ANTI-INFLAMMATORY AGENTS;
CRITICAL PATHWAYS;
DECISION SUPPORT TECHNIQUES;
DRUG MONITORING;
GASTROENTEROLOGY;
GASTROINTESTINAL AGENTS;
HUMANS;
INFLAMMATORY BOWEL DISEASES;
PREDICTIVE VALUE OF TESTS;
TREATMENT OUTCOME;
|
|
EID: 85028632487
PISSN: 00165085
EISSN: 15280012
Source Type: Journal
DOI: 10.1053/j.gastro.2017.07.039 Document Type: Article |
|
Times cited : (8)
|
|
References (0)
|